Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Veenstra

Showing results (1-10 of 209) with videos related to

Pageof 21
Sort By:
Pharmacogenetics|July 13, 2004
Bringing genomics to the bedside: a cost-effective pharmacogenomic test?David L Veenstra
Pharmacoeconomics|October 15, 2008
A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis BD Eldon Spackman, David L Veenstra
JAMA|September 22, 2011
Evolving research and stakeholder perspectives on pharmacogenomicsAmber L Beitelshees, David L Veenstra
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 24, 2009
The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancerLouis P Garrison, David L Veenstra
The American Journal of Managed Care|July 18, 2003
Managed care in the genomics era: assessing the cost effectiveness of genetic testsMitchell K Higashi, David L Veenstra
Pharmacogenetics and Genomics|January 21, 2006
Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysisLisa M Meckley, David L Veenstra
Pharmacotherapy|August 30, 2008
Warfarin pharmacogeneticsNita A Limdi, David L Veenstra
Journal of Clinical Epidemiology|December 10, 2009
Expectations, validity, and reality in pharmacogeneticsNita A Limdi, David L Veenstra
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 1, 2020
Economic value of exome sequencing for suspected monogenic disordersBart S Ferket, David L Veenstra
Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 10, 2012
A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomicsPreeti S Bajaj, David L Veenstra
Pageof 21

Showing results (1-10 of 209) with videos related to

Sort By:
Pageof 21
Pharmacogenetics|July 13, 2004
Bringing genomics to the bedside: a cost-effective pharmacogenomic test?David L Veenstra
Pharmacoeconomics|October 15, 2008
A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis BD Eldon Spackman, David L Veenstra
JAMA|September 22, 2011
Evolving research and stakeholder perspectives on pharmacogenomicsAmber L Beitelshees, David L Veenstra
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 24, 2009
The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancerLouis P Garrison, David L Veenstra
The American Journal of Managed Care|July 18, 2003
Managed care in the genomics era: assessing the cost effectiveness of genetic testsMitchell K Higashi, David L Veenstra
Pharmacogenetics and Genomics|January 21, 2006
Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysisLisa M Meckley, David L Veenstra
Pharmacotherapy|August 30, 2008
Warfarin pharmacogeneticsNita A Limdi, David L Veenstra
Journal of Clinical Epidemiology|December 10, 2009
Expectations, validity, and reality in pharmacogeneticsNita A Limdi, David L Veenstra
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 1, 2020
Economic value of exome sequencing for suspected monogenic disordersBart S Ferket, David L Veenstra
Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 10, 2012
A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomicsPreeti S Bajaj, David L Veenstra
Pageof 21